Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity

Cancer Research

Volumn 69, Issue 23, 2009, Pages 8996-9002

  Van Waterschoot, Robert A B ^a   Lagas, Jurjen S ^a   Wagenaar, Els ^a   Van Der Kruijssen, Cornelia M M ^a   Van Herwaarden, Antonius E ^a   Song, Ji Ying ^a   Rooswinkel, Rogier W ^a   Van Tellingen, Olaf ^a   Rosing, Hilde ^b   Beijnen, Jos H ^b   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; DOCETAXEL; GLYCOPROTEIN P;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DETOXIFICATION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; GASTROINTESTINAL TOXICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; INTESTINAL DISEASES; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; TAXOIDS;

EID: 71549157438     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2915     Document Type: Article

References (25)

1. Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 2006;45:235-252 (Pubitemid 43327491)
2. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of Taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998;8:391-401. (Pubitemid 28475303)
3. Sparreboom A, Van Tellingen O, Scherrenburg EJ, et al. Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos 1996;24:655-658 (Pubitemid 26000768)
4. Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62:6158-6164 (Pubitemid 35244466)
5. Kuppens IE, Bosch TM, van Maanen MJ, et al. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol 2005;55:72-78
6. Malingre MM, Richel DJ, Beijnen JH, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001;19:1160-1166
7. Oostendorp RL, Huiteman AD, Rosing H, et al. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin Cancer Res 2009;15:4228-4233
8. Thummel KE. Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest 2007;117:3173-3176 (Pubitemid 350096972)
9. Kivisto KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 2004;18:621-626 (Pubitemid 39564261)
10. Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 2001; 50:S3-11.
11. Ito K, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - theoretical approach. Pharm Res 1999;16:225-231 (Pubitemid 29135126)
12. Garmire LX, Hunt CA. In silico methods for unraveling the mechanistic complexities of intestinal absorption: metabolism-efflux transport interactions. Drug Metab Dispos 2008;36:1414-1424
13. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997;27:161-170 (Pubitemid 27417871)
14. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999;16:408-414 (Pubitemid 29162099)
15. Benet LZ, Cummins CL, Wu CY. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003;4: 393-398
16. Knight B, Troutman M, Thakker DR. Deconvoluting the effects of P-glycoprotein on intestinal CYP3A: a major challenge. Curr Opin Pharmacol 2006;6:528-532 (Pubitemid 44340667)
17. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 1997;94:4028-4033 (Pubitemid 27180493)
18. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, et al. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007;117:3583-3592 (Pubitemid 350097013)
19. Kuppens IE, van Maanen MJ, Rosing H, Schellens JH, Beijnen JH. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr 2005;19: 355-361 (Pubitemid 40990725)
20. Lagas JS, van Waterschoot RA, van Tilburg VA, et al. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res 2009;15:2344-2351
21. van Waterschoot RA, van Herwaarden AE, Lagas JS, et al. Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol 2008;73:1029-1036
22. van Waterschoot RA, Rooswinkel RW, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Schinkel AH. Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. FASEB J 2009;23:224-231
23. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, Andre S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995;22:3-16.
24. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 1995;6:339-55, 363-368
25. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57. (Pubitemid 30055093)